Cargando…

Inhaled nitric oxide and acute kidney injury risk: a meta-analysis of randomized controlled trials

PURPOSE: There are conflicting results as to the effect of inhaled nitric oxide (iNO) therapy on the risk of acute kidney injury (AKI). The aim of this study was to perform a meta-analysis to assess the updated data. METHODS: We systematically searched Web of Science, the Cochrane Library, Wanfang,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junqiu, Cong, Xuhui, Miao, Mengrong, Yang, Yitian, Zhang, Jiaqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850389/
https://www.ncbi.nlm.nih.gov/pubmed/33494652
http://dx.doi.org/10.1080/0886022X.2021.1873805
Descripción
Sumario:PURPOSE: There are conflicting results as to the effect of inhaled nitric oxide (iNO) therapy on the risk of acute kidney injury (AKI). The aim of this study was to perform a meta-analysis to assess the updated data. METHODS: We systematically searched Web of Science, the Cochrane Library, Wanfang, and PubMed for relevant randomized control trials between database inception and 9/07/2020. Relative risks (RRs) with 95% confidence intervals (CIs) predicting the risk of AKI were extracted to obtain summary estimates using fixed-effects models. The Trim and Fill method was used to evaluate the sensitivity of the results and adjust for publication bias in meta-analysis. RESULTS: 15 randomized controlled studies from 14 articles involving 1853 patients were included in the study. Analyzing the eligible studies we found: (1) iNO therapy significantly increased the risk of AKI in acute respiratory distress syndrome patients (RR 1.55, 95% CI 1.15–2.10, p = 0.004; I(2) for heterogeneity 0%; P(het) = 0.649). (2) The use of iNO was associated with reduced AKI risk in patients undergoing cardiac surgery (RR 0.80, 95% CI 0.64–0.99, p = 0.037; I(2) for heterogeneity 0%; P(het) = 0.528). (3) For organ transplantation recipients, there was no effect of iNO administration on the risk of AKI (RR 0.50, 95% CI 0.16–1.56, p = 0.233; I(2) for heterogeneity 0%; P(het) = 0.842). The Trim and Fill analysis showed that the overall effect of this meta-analysis was stable. CONCLUSIONS: The effect of iNO on AKI risk might be disease-specific. Future RCTs with larger patient populations should aim to validate our findings.